Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-PNP With and Without Tirzepatide in MASLD
NCT07527910Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2026
- Primary completion
- Mar 2030
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of pivicasiran in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Regeneron Pharmaceuticals. Started May 2026; status: recruiting.
02
Drugs
pivicasiran
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT07527910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07527910.